Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study

被引：0

作者：

Barni, S. ^{[1
]}

Fontanella, C. ^{[2
]}

Del Mastro, L. ^{[3
]}

Livraghi, L. ^{[4
]}

Morritti, M. ^{[5
]}

Pizzuti, L. ^{[6
]}

Michelotti, A. ^{[7
]}

Lutrino, E. S. ^{[8
]}

Ciccarese, M. ^{[9
]}

Musolino, A. ^{[10
]}

Quercia, S. ^{[11
]}

Garrone, O. ^{[12
]}

Pellegrino, A. ^{[13
]}

Pistelli, M. ^{[14
]}

Martella, F. ^{[15
]}

Iezzi, L. ^{[16
]}

Mentuccia, L. ^{[17
]}

Latorre, A. ^{[18
]}

D'Onofrio, L. ^{[19
]}

Porcu, L. ^{[20
]}

机构：

[1] Azienda Osped Treviglio, Med Oncol, Treviglio, Italy

[2] Azienda Osped Univ Udine, Med Oncol, Udine, Italy

[3] Ist Nazl Ric Canc, IRCCS San Martino IST, Genoa, Italy

[4] Azienda Osped Papa Giovanni XXIII, Med Oncol, Bergamo, Italy

[5] IRCSS Casa Sollievo Sofferenza, Med Oncol, San Giovanni Rotondo, Italy

[6] Ist Nazl Tumori Regina Elena, Med Oncol B, Rome, Italy

[7] Azienda Osped Univ Pisana, Med Oncol 1, Pisa, Italy

[8] Osped A Perrino, Med Oncol Breast Unit, Brindisi, Italy

[9] PO Fazzi, Med Oncol, Lecce, Italy

[10] Azienda Osped Univ Parma, Med Oncol, Parma, Italy

[11] Osped S Orsola Malpighi, Addarii Med Oncol, Bologna, Italy

[12] AOS Croce Carle, Med Oncol, Cuneo, Italy

[13] Osped San Pietro FBF, Med Oncol, Rome, Italy

[14] Univ Politecn Marche AO Osped Riuniti, Med Oncol, Ancona, Italy

[15] Azienda Sanit Firenze, Med Oncol, Florence, Italy

[16] PO SS Annunziata, Clin Oncol, Chieti, Italy

[17] Osped Santissima Trinita, Med Oncol, Sora Fr, Italy

[18] Ist Tumori Giovanni Paolo II, Med Oncol, Bari, Italy

[19] Univ Campus Biomedico, Med Oncol, Rome, Italy

[20] IRCCS Ist Ric Farmacol Mario Negri, Lab Metodol Ric Biomed, Milan, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30799-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1849

引用

页码：S281 / S282

页数：2

共 50 条

[1] A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study.
Barni, Sandro
Fontanella, Caterina
Del Mastro, Lucia
Livraghi, Luca
Pizzuti, Laura
Morritti, Maria
Lutrino, Stefania Eufemia
Ciccarese, Mariangela
Garrone, Ornella
Michelotti, Andrea
Latorre, Agnese
d'Onofrio, Loretta
Pellegrino, Arianna
Leonardi, Vita
Iezzi, Laura
La Verde, Nicla Maria
Airoldi, Mario
Pistelli, Marco
Martella, Francesca
Porcu, Luca
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study
Barni, Sandro
Livraghi, Luca
Gravina, Adriano
Martella, Francesca
D'Onofrio, Loretta
Morritti, Maria
Michelotti, Andrea
Vici, Patrizia
Mentuccia, Lucia
Porcu, Luca
Orditura, Michele
Puglisi, Fabio
Poletti, Paola
Caremoli, Elena Rota
Ghilardi, Laura
Maiello, Evaristo
Morritti, Maria
Vici, Patrizia
Pizzuti, Laura
Michelotti, Andrea
De Angelis, Claudia
Landucci, Elisabetta
Cinieri, Saverio
Orlando, Laura
Fedele, Palma
Ciccarese, Mariangela
Forcignano, Rosachiara
Leo, Silvana
Musolino, Antonino
Boggiani, Daniela
Zamagni, Claudio
Rubino, Daniela
Garrone, Ornella
Vandone, Anna Maria
Martella, Francesca
Fioretto, Luisa
Puglisi, Fabio
Fontanella, Caterina
Berardi, Rossana
Pistelli, Mirco
Del Mastro, Lucia
D'Alonzo, Alessia
Natoli, Clara
Grassadonia, Antonino
Mentuccia, Lucia
Zoratto, Federica
Santini, Daniele
D'Onofrio, Loretta
Giotta, Francesco
Latorre, Agnese
JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (06) : 990 - 993
[3] Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
Gamucci, Teresa
Michelotti, Andrea
Pizzuti, Laura
Mentuccia, Lucia
Landucci, Elisabetta
Sperduti, Isabella
Di Lauro, Luigi
Fabi, Alessandra
Tonini, Giuseppe
Sini, Valentina
Salesi, Nello
Ferrarini, Ilaria
Vaccaro, Angela
Pavese, Ida
Veltri, Enzo
Moscetti, Luca
Marchetti, Paolo
Vici, Patrizia
JOURNAL OF CANCER, 2014, 5 (05): : 320 - 327
[4] Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study
Barni, Sandro
Livraghi, Luca
Morritti, Maria
Vici, Patrizia
Michelotti, Andrea
Cinieri, Saverio
Fontanella, Caterina
Porcu, Luca
Del Mastro, Lucia
Puglisi, Fabio
FUTURE ONCOLOGY, 2019, 15 (01) : 3247 - 3258
[5] Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study.
Liu, Liping
Hu, Zhe-Yu
Xie, Ning
Yang, Xiaohong
Xiao, Huawu
Li, Jing
Tian, Can
Wu, Hui
Lu, Jun
Gao, Jianxiang
Hu, Xuming
Cao, Min
Shui, Zhengrong
Liu, Bingliang
Ouyang, Quchang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
Kenny, Laura
Beresford, Mark
Brown, Ian
Misra, Vivek
Kristeleit, Hartmut
EUROPEAN JOURNAL OF CANCER CARE, 2022, 31 (06)
[7] Phase 2 study of eribulin mesylate in combination with carboplatin in patients with advanced triple negative breast cancer.
Michalaki, Vasiliki
Karvouni, Eleni
Dafnios, Nikolaos
Psychogios, Christos
Vasiliou, John
Papadimitriou, Christos A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Eribulin mesylate in breast cancer
Verdaguer, Helena
Morilla, Idoia
Urruticoechea, Ander
WOMENS HEALTH, 2013, 9 (06) : 517 - 526
[9] Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN)
Patsouris, A.
Septans, A. L.
Paillard, M. J.
Pivot, X.
Soibinet, P.
Jovenin, N.
Robert, M.
Gourmelon, C.
Korembaum, C.
Petit, T.
Martin-Babau, J.
Brunot, A.
Lefeuvre-Plesse, C.
Adele, M.
Bourgeois, H.
Som, M.
Uwer, L.
Campone, M.
Campion, L.
Tredan, O.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S287 - S287
[10] Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study (vol 15, pg 33, 2019)
Barni, Sandro
Livraghi, Luca
Morritti, Maria
Vici, Patrizia
Michelotti, Andrea
Cinieri, Saverio
Fontanella, Caterina
Porcu, Luca
Del Mastro, Lucia
Puglisi, Fabio
Ciccarese, Mariangela
Forcignano, Rosachiara
FUTURE ONCOLOGY, 2019, 15 (21) : 2555 - 2555

← 1 2 3 4 5 →